FOR IMMEDIATE RELEASE
Josh Berkowitz: (703) 939-7056
Kyra Sanborn: (617) 496-1507
Two state Medicaid programs have eliminated prior authorization requirements for hepatitis C treatment as of January 2022, joining a growing number of states to increase access to treatment for Medicaid recipients.
WASHINGTON, D.C. (January 20, 2022) – The Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR) today recognize the Virginia and Alaska state Medicaid programs for removing prior authorization requirements for hepatitis C treatment, effective in each state as of January 2022. Virginia and Alaska become the tenth and eleventh states in the country to remove prior authorizations for hepatitis C treatment for most patients, joining a growing number of states to increase access for Medicaid recipients.
Prior to the policy change, prescribing hepatitis C treatment in Virginia and Alaska involved a cumbersome process. Providers were required to submit pages of paperwork to justify the medical necessity for treatment, including information on the individual’s substance use history, laboratory results, and other information. Though many states still require prior authorization for hepatitis C treatment, more states are eliminating barriers to treatment access for Medicaid recipients, who are disproportionately impacted by hepatitis C.
In Virginia, the number of acute, perinatal and chronic cases of hepatitis C significantly increased between 2018-2019; and Alaska had a 20% increase in hepatitis C cases between 2012-2018, based on publicly available data. In 2019, the rate of newly reported chronic hepatitis C cases was highest among American Indian/Alaska Native persons (86.7 cases per 100,000 population), compared with other racial/ethnicity categories. National trends indicate a rise in hepatitis C case incidence, caused in large part by the opioid crisis, as well as a decrease in hepatitis C treatment levels over the past several years.
“We are thrilled to see Virginia and Alaska follow the lead of other states across the country to remove burdensome prior authorization requirements on hepatitis C treatments for Medicaid recipients. Increasing access to curative treatments for historically marginalized populations is imperative to adequately addressing the hepatitis C epidemic,” said Robert Greenwald, Faculty Director for the Center for Health Law and Policy Innovation.
Cases of hepatitis C, a viral infection that causes liver inflammation and is one of the leading causes of liver disease, have been increasing since 2010 due to the ongoing opioid crisis. Complications from hepatitis C can be fatal if left untreated, however innovative direct-acting antiviral drugs can cure most people in 8 to 12 weeks. Yet barriers to this treatment persist across the country.
“As a native Virginian, I’m proud to see the steps that the Commonwealth has taken to eliminate prior authorizations for hepatitis C treatment,” said Adrienne Simmons, Director of Programs at NVHR. “Communities of color in both Virginia and Alaska continue to be disproportionately impacted by the opioid crisis and the hepatitis C epidemic. In addition to increasing access to treatment for hepatitis C, states must use effective and equitable harm reduction, screening, and linkage to care strategies that prioritize the people who need care most.”
For more information about hepatitis C treatment access barriers, please visit www.stateofhepc.org. View the State of Hep C’s latest project update here.
About the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI)
The Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) advocates for legal, regulatory, and policy reforms to improve the health of marginalized populations, with a focus on the needs of low-income people living with chronic illnesses and disabilities. CHLPI works with consumers, advocates, community-based organizations, health and social services professionals, government officials, and others to expand access to high-quality health care; to reduce health disparities; to develop community advocacy capacity; and to promote more equitable and effective health care systems. CHLPI is a clinical teaching program of Harvard Law School and mentors students to become skilled, innovative, and thoughtful practitioners as well as leaders in health and public health law and policy. For more information, visit www.chlpi.org.
About the National Viral Hepatitis Roundtable (NVHR)
The National Viral Hepatitis Roundtable, an initiative of HEP, is a national coalition fighting for an equitable world free of viral hepatitis. NVHR seeks to eliminate viral hepatitis in the United States and improve the lives of those affected through advocacy, education, and support to national, state and local partners. For more information, visit www.nvhr.org.